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Abstract Tedizolid phosphate is approved for the treat-
ment of acute bacterial skin and skin structure infections.
To determine whether the expected dose of tedizolid
phosphate can be delivered via nasogastric tube in patients
who have difficulty swallowing and in whom venous
access is not suitable, this in vitro study evaluated the
recovery of tedizolid phosphate 200-mg tablets after
crushing, dispersion in water, and passage through a
nasogastric tube. To analyze the chemical stability of the
crushed tablet dispersed in water, the aqueous preparation
was assayed initially after dispersion and again after 4 h at
room temperature. Recovery of tedizolid phosphate after
the crushed tablets were dispersed in water and passed
through nasogastric tubes ranged from 92.5 to 97.1 %,
which is within the specified acceptance criteria of 90 to
110 %. There was no significant change in recovery values
after 4 h of storage at room temperature (93.9 % initially
and 94.7 % after 4 h). The stability and recovery findings
support the feasibility of administering an aqueous dis-
persion of crushed tedizolid phosphate tablets through a
nasogastric tube in patients who have difficulty swallowing
and in whom intravenous administration is not possible.
Key Points
Crushed tedizolid phosphate 200-mg tablets are
stable for at least 4 h after being dispersed in water.
The ability to administer aqueous dispersions of
crushed tedizolid phosphate tablets through a
nasogastric tube with acceptable recovery was
demonstrated.
The administration of crushed tedizolid phosphate
200-mg tablets, compared with whole tablets, is
unlikely to alter the pharmacokinetics of tedizolid.
1 Introduction
Acute bacterial skin and skin structure infections (ABSS-
SIs), which include cellulitis/erysipelas, wound infections,
and major cutaneous abscesses, are an increasing cause of
hospitalization and are an indication for antibacterial
therapy globally [1–4]. Tedizolid phosphate, the prodrug of
the active moiety tedizolid, is an oxazolidinone antibacte-
rial approved for the treatment of ABSSSI in adults [5, 6].
The approved regimen for both intravenous and oral
administration is 200 mg once daily for 6 days [5]. Tedi-
zolid exerts its antibacterial activity by binding to the 23s
ribosomal RNA (rRNA) component of the large subunit
(50S) of the bacterial ribosome, resulting in inhibition of











1 Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth,
NJ 07033, USA
2 MSD, Kriens, Switzerland
Drugs R D (2015) 15:329–333
DOI 10.1007/s40268-015-0108-6
wide range of Gram-positive pathogens, including resistant
strains such as methicillin-resistant Staphylococcus aureus
and vancomycin-resistant enterococci (VRE) [8–10]. Two
phase III trials, ESTABLISH-1 and ESTABLISH-2,
demonstrated the noninferior efficacy of tedizolid (200 mg
once daily for 6 days) to linezolid (600 mg twice daily for
10 days), and that tedizolid was generally well tolerated in
patients with ABSSSI [11–13].
Tedizolid phosphate is rapidly converted to tedizolid in
the body by nonspecific endogenous phosphatases [14, 15]
and freely distributes into tissues [16]. After oral admin-
istration at the standard therapeutic dose of 200 mg, the
absolute bioavailability of tedizolid is 91 %, allowing
intravenous and oral forms to be interchanged at the same
dose [17]. The pharmacokinetics of tedizolid are not
affected by patient age, sex, weight, body mass index,
renal/hepatic impairment, or administration with or without
food [14, 18, 19]. The solubility of the drug is highest when
fully deprotonated at a high pH and lowest when fully
protonated at a low pH, with a steep increase in solubility
between pH 4.0 and 6.0 [20].
It is common practice to crush solid oral formulations,
such as tablets, and disperse them in various solutions or
food/beverages to facilitate administration to patients who
have difficulty swallowing [21]. In patients who may have
difficulty swallowing, insertion of a nasogastric tube
facilitates feeding and drug delivery. Results of a previous
study [14] showed that the clinical pharmacokinetics of
tedizolid was similar for orally administered tedizolid
phosphate powder in a capsule and tedizolid phosphate
tablets, suggesting that crushing the tablets would not alter
the pharmacokinetics of tedizolid, provided no drug was
lost during administration. Delivering an accurate dose of
crushed tedizolid phosphate via nasogastric tube would be
a valuable alternative to oral tablets or intravenous
administration for patients who have difficulty swallowing
and are not suitable to receive venous access (e.g., geriatric
or other patients in whom insertion and maintenance of an
intravenous line is not feasible). To determine the feasi-
bility of administering tedizolid phosphate via nasogastric
tube, this in vitro study evaluated the stability and recovery
of tedizolid phosphate 200-mg tablets after crushing, dis-
persal in water, and passage through a nasogastric tube.
2 Methods
2.1 Crushing of Tedizolid Phosphate Tablets
and Passage through a Nasogastric Tube
Each 200-mg tablet of tedizolid phosphate was crushed to a
fine powder using a screw-style tablet crusher (Apex-Carex
Health Care, Sioux Falls, SD, USA). The fine powder was
poured from the crusher to a 100-ml glass beaker. Water
(30 ml) was added to the beaker and gently swirled to
thoroughly wet and disperse the fine powder. Disintegra-
tion of the tablet was confirmed by visual inspection. A
nasogastric tube was attached to the tip of a 60-ml syringe
with the plunger removed. After an initial 30-ml flush with
sterile water, the aqueous dispersion of tedizolid phosphate
was passed through the syringe and gravity fed through the
nasogastric tube by slowly pouring the tablet dispersion
into a syringe attached to the nasogastric tube. The
administration was followed by up to three 15-ml rinses of
the beaker and an additional 30-ml sterile water flush. This
is consistent with methodology of nasogastric tube usage in
clinical practice [22]. The samples were collected in vol-
umetric flasks. Assays were run in triplicate with two types
of commercial nasogastric tubes that varied in dimension
and material: type 1, Kangaroo nasogastric feeding tube,
10-French 4300 (109 cm) (Covidien Ref 8884-721088);
type 2, Salem sump dual-lumen stomach tube, 18-French/
CH (6.0 mm) 4800 (122 cm) (Covidien Ref 8888264986).
The volumetric flasks were brought up to volume with
extraction solvent and further diluted for potency analysis.
2.2 Stability of Tedizolid Phosphate/Water
Preparation
The stability of tedizolid phosphate was evaluated by
preparing two separate samples of a crushed tablet dis-
persed in water. One preparation was assayed immediately,
and the other was assayed after storage at room tempera-
ture for 4 h.
2.3 Recovery of Tedizolid Phosphate
The aqueous solutions of crushed tedizolid phosphate were
assayed for recovery by high-performance liquid chro-
matography with ultraviolet detection (HPLC-UV). HPLC
separation was performed at 40 C using gradient elution
with 25 mM ammonium acetate buffer (pH 8.5) and a
mixture of 90 % acetonitrile and 10 % tetrahydrofuran as
the mobile phase. The method used a 4.6- by 150-mm col-
umn with US Pharmacopeia L1 packing material. The UV
detection was set at 300 nm. The volume of all injections
was 5 ll, and the total run time was 37 min. The amount and
percentage dose recovery of tedizolid phosphate were
measured. The inter-assay accuracy was shown to be within
1.2 % (actual) throughout the analytical run. The inter-assay
precision was shown to be within 0.27 % (actual).
2.4 Limits
The prespecified limit for tedizolid phosphate in recovery
samples was 90 to 110 % of the dose per 200-mg tablet.
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The product specification limit for tedizolid was 1.0 % and
0.2 % for unspecified impurities. The limits were consis-
tent with the shelf-life specification for the drug product.
3 Results
3.1 Recovery of Tedizolid Phosphate
The recovery of tedizolid phosphate after crushing the
tedizolid phosphate tablet, dispersing the tablet in water,
and passing the dispersed material through a nasogastric
tube ranged from 92.5 to 97.1 % of the 200-mg tablet
(Table 1). The recovery was 95.8 ± 1.1 % (mean ± stan-
dard deviation) for nasogastric tube type 1 and
93.6 ± 1.7 % for nasogastric tube type 2. The mean and
individual replicate recovery values for tedizolid phosphate
were within the prespecified limits of 90 to 110 % after
passage through both types of nasogastric tubes.
Levels of specified degradation products (i.e., tedizolid)
and unspecified impurities (relative retention time [RRT]
1.37) were also within approved shelf-life specification for
the drug product (Table 2). The observed level of the
degradation product tedizolid ranged from\0.05 to 0.14 %
after the tablet was crushed, dispersed in water, and passed
through a nasogastric tube. The level of unspecified
impurity (RRT 1.37) was consistently around 0.05 %.
3.2 Stability of Tedizolid Phosphate
The crushed tedizolid phosphate tablet dispersed in water
was stable for at least 4 h at room temperature (94.7 %
dose recovery), which was similar to the stability at initial
dispersion (93.9 % dose recovery) (Table 3). The per-
centage area by HPLC of the degradation products (tedi-
zolid) and the unspecified impurities (RRT 1.37) were
approximately 0.05 % and were also within the shelf-life
impurity specification of the drug product.
4 Discussion
Before this study, no information was available regarding
the stability and recovery of tedizolid phosphate 200-mg
tablets when crushed and dispersed in water or on the
feasibility of administering tedizolid phosphate through a
nasogastric tube. This in vitro study showed that tedizolid
phosphate has minimal loss after crushing, dispersal in
water, and simulated passage through two types of naso-
gastric tubes, with measurable levels exceeding 93 %. The
crushed suspension of tedizolid phosphate was stable for at
least 4 h, with excellent recovery and minimal degradation.
Table 1 Recovery of tedizolid phosphate after passage through
nasogastric tube
NG tube Recovery of 200-mg dose commercial tablet (%)
Replicate 1 Replicate 2 Replicate 3 Mean (SD)
Type 1a 95.2 97.1 95.1 95.8 (1.1)
Type 2b 92.5 95.6 92.8 93.6 (1.7)
NG nasogastric, SD standard deviation
a Type 1, Kangaroo nasogastric feeding tube, 10-French 4300
(109 cm) (Covidien Ref 8884-721088)
b Type 2, Salem sump dual-lumen stomach tube, 18-French/CH
(6.0 mm) 4800 (122 cm) (Covidien Ref 8888264986)
Table 2 Levels of degradation
products and impurities
NG tube Tedizolid (% area by HPLC) Unspecified RRT 1.37 (% area by HPLC)
Replicate 1 Replicate 2 Replicate 3 Replicate 1 Replicate 2 Replicate 3
Type 1a 0.13 0.14 0.05 0.05 0.05 0.05
Type 2b 0.06 0.05 \0.05 0.05 0.06 0.05
HPLC high-performance liquid chromatography, NG nasogastric, RRT relative retention time
a Type 1, Kangaroo nasogastric feeding tube, 10-French 4300 (109 cm) (Covidien Ref 8884-721088)
b Type 2, Salem sump dual lumen stomach tube, 18-French/CH (6.0 mm) 4800 (122 cm) (Covidien Ref
8888264986)
Table 3 Stability of water
preparation of tedizolid
phosphate and levels of
degradation products/impurities
after incubation
Time (h) Recovery of 200-mg dose
commercial tablet (%)
Tedizolid
(% area by HPLC)
Unspecified RRT 1.37
(% area by HPLC)
0 93.9 \0.05 0.05
4 94.7 0.05 0.06
HPLC high-performance liquid chromatography, RRT relative retention time
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These results suggest that the expected dose of tedizolid
phosphate 200 mg can be delivered via nasogastric tube
after crushing and dispersing in water, therefore accom-
modating patients who have difficulty swallowing.
Recovery of crushed tedizolid phosphate tablets was
excellent using a commercially available tablet crusher and
two types of nasogastric tubes. Length, diameter, and
composition of the tested tubes differed, suggesting that the
type of nasogastric tube is unlikely to influence recovery of
tedizolid phosphate from a crushed preparation and would
therefore not be a consideration in the decision to admin-
ister a crushed tedizolid suspension. Together with previ-
ous results showing that the clinical pharmacokinetics for
tedizolid phosphate powder in a capsule and tedizolid
phosphate tablets were comparable [14], the findings from
this study suggest that tablet crushing with or without
nasogastric tube administration is unlikely to alter the
pharmacokinetics of tedizolid. The dispersed solution of
crushed tedizolid phosphate was stable for at least 4 h at
room temperature, providing sufficient time to use this
alternative means of dosing.
5 Conclusions
This study showed that 200-mg tedizolid phosphate tablets
can be crushed, dispersed in water, and delivered through a
nasogastric tube, with minimal losses. Therefore, naso-
gastric tube administration might be a viable alternative to
oral tablets or intravenous administration of tedizolid
phosphate, particularly for patients who have difficulty
swallowing but for whom venous access is not suitable.
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